Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Aug 13, 2022 4:43am
265 Views
Post# 34893612

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Isolated data on the optimized group

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Isolated data on the optimized groupFred wrote:

"Interesting topic - so cancer cells that have received an exceptional but not overwhelming dose of ROS can thereby be primed to be more resistant to subsequent exposure - something in the nature of a vaccine?"

My thinking is that, in general, a patient who receives an ROS-inducing treatment that is sub-therapeutic (either with regards to dosage &/or dosing frequency) could lead to two undesirable effects: 1).  Promote resistance via the survival/growth of more highly ROS-adaptable cancer cells & 2).  Cause an above baseline increase in intracellular ROS concentration that is non-toxic/non-lethal to a cancer cell, but that could possibly promote tumor development in any healthy cells that had sufficient uptake of drug to impact ROS levels detrimentally.  This is why enhanced tumor selectivity (in addition to proper drug/MoA & dosing) is key.  Fortunately, TLD1433/Rutherrin is highly selective for cancer cells...but clinically speaking, there's no treatment I'm aware of that's 100% selective.
<< Previous
Bullboard Posts
Next >>